Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study
Pivotal Phase II study shows mosunetuzumab achieves 60% complete response in R/R follicular lymphoma, highlighting long-term efficacy and safety.
Key Points
Median follow-up of 60 months revealed 78% response rates, maintaining a 60% complete response rate in treated patients with relapsed/refractory follicular lymphoma.
Overall response rate and complete response rate were consistent, with 61 months median progression-free survival for patients achieving complete response.
Treatment included fixed-duration mosunetuzumab with standard monitoring and reported adverse events primarily of low grade, indicating a manageable safety profile.
B-cell recovery and normalization of immunoglobulin M levels were observed in the majority of patients, emphasizing long-term effects post-treatment.